Evidence map›Paper›PMID 35013591›Full record

ArticleNature microbiology2022

Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California.

Venice Servellita, Mary Kate Morris, Alicia Sotomayor-Gonzalez, Amelia S Gliwa, Erika Torres, Noah Brazer, Alicia Zhou, Katherine T Hernandez, Madeline Sankaran, Baolin Wang and 18 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Does the COVID-19 Vaccination Reduce the Risk to Transmit SARS-CoV-2 to Others?Advances in experimental medicine and biology · 2024
    Review
  5. Article
  6. Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 5 institutions in 1 country.

Venice ServellitaDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
Mary Kate MorrisViral and Rickettsial Disease Laboratory, California Department of Public Health, Richmond, CA, USA.
Alicia Sotomayor-GonzalezDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
Amelia S GliwaDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
Erika TorresColor Genomics, Inc., Burlingame, CA, USA.
Noah BrazerDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
Alicia ZhouColor Genomics, Inc., Burlingame, CA, USA.
Katherine T HernandezSan Francisco Department of Public Health, San Francisco, CA, USA.
Madeline SankaranSan Francisco Department of Public Health, San Francisco, CA, USA.
Baolin WangDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
Daniel WongDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
Candace WangDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
Yueyuan ZhangDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
Kevin R ReyesDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
Dustin GlasnerDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-9821-6683
Xianding DengDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
Jessica StreithorstDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
Steve MillerDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
Edwin FriasAbbott Laboratories, Abbott Park, IL, USA.
Mary RodgersAbbott Laboratories, Abbott Park, IL, USA.
Gavin ClohertyAbbott Laboratories, Abbott Park, IL, USA.
John HackettAbbott Laboratories, Abbott Park, IL, USA.
Carl HansonViral and Rickettsial Disease Laboratory, California Department of Public Health, Richmond, CA, USA.
Debra WadfordViral and Rickettsial Disease Laboratory, California Department of Public Health, Richmond, CA, USA.ORCID http://orcid.org/0000-0002-8630-427X
Susan PhilipSan Francisco Department of Public Health, San Francisco, CA, USA.
Scott TopperColor Genomics, Inc., Burlingame, CA, USA.
Darpun SachdevSan Francisco Department of Public Health, San Francisco, CA, USA.
Charles Y ChiuDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA. charles.chiu@ucsf.edu.ORCID http://orcid.org/0000-0003-2915-2094
University of California, San Francisco · USAbbott Fund · USSan Francisco Department of Public Health · USCalifornia Department of Public Health · USColor (United States) · US

Funding

Real-Time Unbiased Pathogen Detection in Febrile Illnesses by Nanopore SequencingR33AI120977 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHIU, CHARLES YEN · 2018 to 2020
$1.6M
Identification of diagnostic and prognostic host biomarkers of Zika virus infection by transcriptome profilingR21AI129455 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHIU, CHARLES YEN · 2017 to 2018
$436k
California Department of Public Health (CDPH) 6NU50CK000539CDC HHS 75D30121C10991NIAID NIH HHS R21 AI129455NIAID NIH HHS R33 AI120977
6 · The paper itself

Abstract

Associations between vaccine breakthrough cases and infection by different SARS coronavirus 2 (SARS-CoV-2) variants have remained largely unexplored. Here we analysed SARS-CoV-2 whole-genome sequences and viral loads from 1,373 persons with COVID-19 from the San Francisco Bay Area from 1 February to 30 June 2021, of which 125 (9.1%) were vaccine breakthrough infections. Vaccine breakthrough infections were more commonly associated with circulating antibody-resistant variants carrying ≥1 mutation associated with decreased antibody neutralization (L452R/Q, E484K/Q and/or F490S) than infections in unvaccinated individuals (78% versus 48%, P = 1.96 × 10

Indexed as

AdolescentAdultAgedAntibodies, NeutralizingAntibodies, ViralBNT162 VaccineBreakthrough InfectionsCohort StudiesCOVID-19COVID-19 VaccinesFemaleGenome, ViralHumansMaleMiddle AgedMutationAntibodies, NeutralizingAntibodies, ViralBNT162 VaccineCOVID-19 Vaccines

Identifiers

PMID35013591
OpenAlexW4220879272

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.